These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 3458444)

  • 41. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Timed-sequential chemotherapy as induction and/or consolidation regimen for younger adults with acute myelogenous leukemia.
    Thomas X; Dombret H
    Hematology; 2007 Feb; 12(1):15-28. PubMed ID: 17364988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
    Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
    Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
    Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
    Montillo M; Mirto S; Petti MC; Latagliata R; Magrin S; Pinto A; Zagonel V; Mele G; Tedeschi A; Ferrara F
    Am J Hematol; 1998 Jun; 58(2):105-9. PubMed ID: 9625576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Low dose cytarabine in the treatment of acute myeloid leukemia. Apropos of 41 cases].
    Frikha M; Elloumi M; Bouaziz M; Daoud J; Mseddi S; Khanfir A; Gargouri J; Souissi T
    Bull Cancer; 1996 Dec; 83(12):996-1001. PubMed ID: 9116380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Circulating immune complexes correlate with remission duration in acute myeloid leukemia.
    Larson RA; Lukin CL; Daly KM; Mick R; Gore S; Le Beau MM
    Leukemia; 1991 Feb; 5(2):131-7. PubMed ID: 2020195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.
    Baer MR; Christiansen NP; Frankel SR; Brunetto VL; Mrózek K; Bloomfield CD; Herzig GP
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):6-12. PubMed ID: 7507264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetics of colony-forming cells (CFU-c) in adult acute leukemia and their prognostic relevance.
    Jehn U; Wachholz K
    Leuk Res; 1983; 7(6):761-70. PubMed ID: 6582343
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
    Minderman H; O'Loughlin KL; Smith PF; Pendyala L; Greco WR; Sweeney KG; Ford LA; Wetzler M; Baer MR
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):73-83. PubMed ID: 16010591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro sensitivity of leukemic cells to nucleoside derivatives in childhood acute leukemias: good activity in leukemic relapses.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Balwierz W; Juraszewska E; Matysiak M; Malinowska I; Stanczak E; Sońta-Jakimczyk D; Szczepanski T; Wachowiak J; Konatkowska B; Balcerska A; Ploszynska A; Kowalczyk J; Stefaniak J; Badowska W; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M
    Neoplasma; 2005; 52(1):74-8. PubMed ID: 15739031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
    List AF; Spier C; Greer J; Wolff S; Hutter J; Dorr R; Salmon S; Futscher B; Baier M; Dalton W
    J Clin Oncol; 1993 Sep; 11(9):1652-60. PubMed ID: 8102639
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS; Lee S; Sikic BI; Paietta E; Wiernik PH; Bennett JM; Rowe JM
    Cancer; 1999 Jan; 85(2):358-67. PubMed ID: 10023703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia: a review and updated results of the Australian Leukemia Study Group.
    Bishop JF; Matthews JP; Young GA; Bradstock K; Lowenthal RM
    Leuk Lymphoma; 1998 Jan; 28(3-4):315-27. PubMed ID: 9517503
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Contributions of host- and disease-related attributes to the outcome of patients with acute myelogenous leukemia.
    Curtis JE; Messner HA; Hasselback R; Elhakim TM; McCulloch EA
    J Clin Oncol; 1984 Apr; 2(4):253-9. PubMed ID: 6368758
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
    Miano M; Pistorio A; Putti MC; Dufour C; Messina C; Barisone E; Ziino O; Parasole R; Luciani M; Lo Nigro L; De Rossi G; Varotto S; Bertorello N; Petruzziello F; Calvillo M; Micalizzi C
    Leuk Lymphoma; 2012 Sep; 53(9):1693-8. PubMed ID: 22303898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.